MOS
NBIX icon

MGO One Seven’s Neurocrine Biosciences NBIX Stock Holding History

MGO One Seven’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,603
Closed -$511K – 1472
2025
Q4 		$511K Buy
+3,603
New +$522K 0.01% 865
2023
Q2 		– Sell
-4,567
Closed -$462K – 869
2023
Q1 		$462K Sell
4,567
-543
-11% -$56.5K 0.03% 502
2022
Q4 		$610K Sell
5,110
-2,270
-31% -$266K 0.06% 335
2022
Q3 		$783 Sell
7,380
-285
-4% -$28.9K 0.03% 289
2022
Q2 		$747K Sell
7,665
-177
-2% -$16.3K 0.1% 227
2022
Q1 		$735K Buy
7,842
+4,339
+124% +$368K 0.08% 275
2021
Q4 		$298K Sell
3,503
-493
-12% -$45.4K 0.03% 496
2021
Q3 		$421K Sell
3,996
-117
-3% -$11.1K 0.05% 372
2021
Q2 		$400K Buy
4,113
+2
+0% +$192 0.06% 392
2021
Q1 		$399K Buy
4,111
+305
+8% +$32K 0.07% 353
2020
Q4 		$365K Sell
3,806
-348
-8% -$33.6K 0.08% 329
2020
Q3 		$399K Buy
+4,154
New +$481K 0.09% 283
2019
Q1 		– Sell
-210
Closed -$14K – 1189
2018
Q4 		$14K Buy
+210
New +$20.1K 0.01% 1032
2018
Q1 		$5K Buy
65
+3
+5% +$253 ﹤0.01% 1317
2017
Q4 		$5K Buy
+62
New +$4.23K ﹤0.01% 1317

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MGO One Seven's NBIX Position: Q1 2026 in Review

MGO One Seven sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 3,603 shares — an estimated $511K sold.

MGO One Seven first reported a position in NBIX in Q4 2017 and held it in 15 quarters. The position peaked at $747K in Q2 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • MGO One Seven reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • MGO One Seven sold 3,603 Neurocrine Biosciences shares in Q1 2026, an estimated $511K.
  • MGO One Seven first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 15 quarters.
  • MGO One Seven's Neurocrine Biosciences position peaked at $747K in Q2 2022.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on MGO One Seven's 13F filing for Q1 2026, filed 14 May 2026.